Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2010
06/15/2010CA2493391C Novel thiophene glycoside derivatives, methods for production thereof, medicaments comprising said compounds and use thereof
06/15/2010CA2491394C 1h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands
06/15/2010CA2481868C Preparation of powder agglomerates
06/15/2010CA2466103C Micelle compositions containing pegylated phospholipids and a photosensitizer
06/15/2010CA2463668C Compositions and kits comprising a defined boron compound, methods of their preparation, and use and administration thereof
06/15/2010CA2442256C Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines with adenosine receptor-binding activity and their use as cardiovascular preparations
06/15/2010CA2441309C Biguanide derivatives
06/15/2010CA2440648C Imidazolidine derivatives, their preparation, and their use as antinflamatory agent
06/15/2010CA2430518C Guanidine and amidine derivatives as factor xa inhibitors
06/15/2010CA2419875C 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridinyl-imidazo[1,2-a]pyrimidin-5(1h)-one derivatives
06/15/2010CA2410253C Regulating lipid levels via the zmax1 or hbm gene
06/15/2010CA2407072C Taste masking coating composition
06/15/2010CA2405050C Production of tcr gamma delta t cells
06/15/2010CA2403168C Condensation derivatives of thiocolchicine and baccatin as antitumor agents
06/15/2010CA2402609C Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
06/15/2010CA2393650C Novel 1,8-naphthyridin-2(1h)-one derivatives
06/15/2010CA2383340C Thienoisoxazolyl- and thienylpyrrazolyl-phenoxy substituted propyl derivatives useful as d4 antagonists
06/15/2010CA2379103C Novel spiro compounds
06/15/2010CA2351714C Semi-hydrochloride of 8-cyano-1-cyclopropyl-7-(1s,6s-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
06/15/2010CA2341700C Compositions and methods for treatment of mitochondrial diseases
06/15/2010CA2335505C Novel triterpenoids and their use for the treatment and prevention of cancer, inflammatory disorders, and neurodegenerative disease
06/15/2010CA2328922C Terminally-branched polymeric linkers and polymeric conjugates containing the same
06/15/2010CA2328440C Heterocyclically substituted amides used as calpain inhibitors
06/15/2010CA2320288C Oligodeoxyribonucleotides comprising o6-benzylguanine and their use
06/15/2010CA2299495C Process for preparing growth hormone secretagogues
06/15/2010CA2285939C Methods and compositions for synthesis of long chain polyunsaturated fatty acids in plants
06/15/2010CA2250080C Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
06/15/2010CA2250000C Methods of modulating melanin synthesis
06/12/2010CA2646383A1 Inhibitors of lethal factor protease of anthrax toxin
06/10/2010WO2010065939A1 Combination therapy to enhace nk cell mediated cytotoxicty
06/10/2010WO2010065936A1 High penetration compositions and their applications
06/10/2010WO2010065932A1 Modified chloroquines with single ring moiety or fused ring moiety
06/10/2010WO2010065923A2 Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
06/10/2010WO2010065918A1 Labeling of target molecules, identification of organelles and other applications, novel compositions, methods and kits
06/10/2010WO2010065917A1 Methods of treating neurological disorders
06/10/2010WO2010065893A1 Raf inhibitors and their uses
06/10/2010WO2010065889A2 Cyclobutanemethanamine inhibitors of monomine reuptake
06/10/2010WO2010065883A2 Method of treating an overweight or obese subject
06/10/2010WO2010065881A2 Methods of treating an overweight or obese subject
06/10/2010WO2010065879A2 Methods of treating an overweight or obese subject
06/10/2010WO2010065865A2 Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
06/10/2010WO2010065852A1 Dimeric avermectin and milbemycin derivatives
06/10/2010WO2010065834A1 Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms
06/10/2010WO2010065825A2 Kinase inhibitors with improved cyp safety profile
06/10/2010WO2010065824A2 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
06/10/2010WO2010065803A1 Substituted piperidine spiro pyrrolidinone and piperidinones used as h3 modulators
06/10/2010WO2010065802A2 Substituted pyrrolidine or imidazolidine melanocortin receptor-specific compounds
06/10/2010WO2010065801A1 Amine substituted piperazine melanocortin receptor-specific compounds
06/10/2010WO2010065800A1 Hydrazine substituted piperidine melanocortin receptor-specific compounds
06/10/2010WO2010065799A2 Amine substituted piperidine melanocortin receptor-specific compounds
06/10/2010WO2010065798A1 Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof
06/10/2010WO2010065787A2 Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
06/10/2010WO2010065782A1 Method for treating pulmonary diseases using rho kinase inhibitor compounds
06/10/2010WO2010065760A1 Imidazo [1,2a] pyridine derivatives, their use as s1p1 agonists and methods for their production
06/10/2010WO2010065756A2 Usirna complexes
06/10/2010WO2010065755A1 Deuterated pyridinones
06/10/2010WO2010065746A2 Piperazine modulators of nk-1 receptors
06/10/2010WO2010065743A2 Bicyclic compounds and methods of making and using same
06/10/2010WO2010065723A1 Methods for prolonging viability of cone cells using modulators of the mammalian target of rapamycine (mtor) pathway
06/10/2010WO2010065717A1 Morpholinone compounds as factor ixa inhibitors
06/10/2010WO2010065709A2 Hydroxamic acid derivatives, preparation and therapeutic uses thereof
06/10/2010WO2010065701A1 Novel polymorphic forms of an azabicyclo-trifluoromethyl benzamide derivative
06/10/2010WO2010065690A1 Crystalline forms
06/10/2010WO2010065685A1 Method of treating c-kit positive relapsed acute myeloid leukemia
06/10/2010WO2010065681A1 Inhibitors of hcv ns5a
06/10/2010WO2010065674A1 Inhibitors of hcv ns5a
06/10/2010WO2010065671A2 Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
06/10/2010WO2010065668A1 Inhibitors of hcv ns5a
06/10/2010WO2010065662A2 Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
06/10/2010WO2010065660A2 Biodegradable polydisulfide amines for gene delivery
06/10/2010WO2010065656A1 Method for reducing blood pressure using inhibitors of plasma kallikrein
06/10/2010WO2010065617A1 Pde1 as a target therapeutic in heart disease
06/10/2010WO2010065586A2 Preparation of capecitabine
06/10/2010WO2010065571A1 Treatment for glomerulonephritis with 2 - [ 4- ( -7-ethyl-5h-pyrrolo [ 2,3-b ] -pyrazin- 6 -yl) propan-2-ol
06/10/2010WO2010065567A2 Methods and compositions for altering health, wellbeing, and lifespan
06/10/2010WO2010065563A2 Apratoxin therapeutic agents: mechanism and methods of treatment
06/10/2010WO2010065512A2 Compounds for treating proliferative disorders
06/10/2010WO2010065491A2 Methods of treating inflammatory disorders
06/10/2010WO2010065449A1 (r) -3- (e) -2- (pyrr0lidin-3-yl) vinyl) -5- (tetrahydr0pyran-4-yl0xy) pyridine, its salts, its synthesis and its use as ligand for nicotinic acetylcholinergic receptors
06/10/2010WO2010065444A1 Drug composition cytotoxic for pancreatic cancer cells
06/10/2010WO2010065443A1 Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
06/10/2010WO2010065433A1 Method of optimizing the treatment of philadelphia-positive leukemia with imatinib mesylate
06/10/2010WO2010065432A1 Nitrooxy derivatives as angiotensin ii receptor antagonists
06/10/2010WO2010065383A1 Calcilytic compounds
06/10/2010WO2010065358A1 Pharmaceutical compositions containing testosterone and an aromatase inhibitor
06/10/2010WO2010065333A1 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds for the treatment of osteoporosis
06/10/2010WO2010065329A2 Nanoparticles for cancer treatment
06/10/2010WO2010065306A1 Treatment of heart tissue via localized delivery of parp inhibitors
06/10/2010WO2010065275A1 Soluble guanylate cyclase activators
06/10/2010WO2010065162A1 Composition for the use to treat alzheimer' s disease
06/10/2010WO2010065159A1 Inhibition of dna polymerases to augment chemotherapeutic and antimicrobial agents
06/10/2010WO2010065134A1 5, 7-dihydro- 6h-pyrimido [ 5, 4-d] [ 1 ] benzazepin-6-thiones as plk inhibitors
06/10/2010WO2010065117A1 Inhibition of hdac2 to promote memory
06/10/2010WO2010065110A2 Antimicrobials
06/10/2010WO2010065085A2 Methods and compositions for treating or preventing pruritis
06/10/2010WO2010065069A2 Compositions comprising renin-angiotensin aldosterone system inhibitors and lipoic acid compounds, and the use thereof for the treatment of renin-angiotensin aldosterone system related disorders
06/10/2010WO2010065024A1 Topical treatment of cataracts in dogs
06/10/2010WO2010064988A1 Bioadhesive patch
06/10/2010WO2010064951A1 New quinoline derivatives, a method for the production and the use thereof for treating microbacterial infections and a pharmaceutical composition based on said derivatives
06/10/2010WO2010064882A1 Thick pine needle extract composition for capsulation
1 ... 2225 2226 2227 2228 2229 2230 2231 2232 2233 2234 2235 2236 2237 2238 2239 2240 2241 2242 2243 2244 2245 ... 7860